Proprietary Stratosome(TM) technology provides a unique formulation, production, and delivery system for economical and scaleable vaccine development

SemBioSys Genetics Inc., a biotechnology company focused on protein-based pharmaceutical and non-pharmaceutical products, announced today that it has been granted U.S. Patent 6,761,914 entitled, "Immunogenic Formulations Comprising Oilbodies." The patent broadly covers composition of matter and methods for preparation and administration of immunogenic formulations involving antigen coated plant seed oilbodies. The Stratosome(TM) Biologics System from SemBioSys offers a unique, cost effective and easily scaleable vaccine production system with potential efficacy improvements.

"This patent broadens our proprietary Stratosome(TM) oilbody based protein production technology, protecting the breadth of its available applications and opening new market opportunities," said Andrew Baum, President and CEO of SemBioSys Genetics Inc. "We have already made significant progress with these new opportunities through the execution of a funded agreement with Dow AgroSciences to evaluate the utility of the Stratosome(TM) technology for the development of an animal vaccine."

This is the sixteenth U.S. patent issued to SemBioSys for its oilbody based protein production technology and the fourth patent issued in the past six months. In June, SemBioSys was issued U.S. Patent 6,750,046 entitled, "Preparation of Thioredoxin and Thioredoxin Reductase Proteins on Oilbodies," and U.S. Patent 6,753,167 entitled, "Preparation of Heterologous Proteins on Oilbodies." In August the Company was granted U.S. Patent 6,777,591 entitled, "Legume-like Storage Protein Promoter Isolated From Flax and Methods of Expressing Proteins in Plant Seeds Using the Promoter." The Company has additional and related patents and patent applications pending worldwide.

Calgary, Alberta-based SemBioSys Genetics Inc. is a privately held biotechnology company focused on the development, commercialization and production of protein-based pharmaceuticals and non-pharmaceutical products based on our plant genetic engineering skills and our proprietary oilbody-oleosin technology platform - the Stratosome(TM) Biologics System. In the past 12 months, SemBioSys has executed five funded partnership agreements with Syngenta Participations AG, Martek Biosciences Corporation, Lonza, Inc., Dow AgroSciences LLC and Arcadia BioSciences, Inc.

Stratosome is a trademark of SemBioSys Genetics Inc.